Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EPS (Basic) (2018 - 2025)

Historic EPS (Basic) for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to -$0.99.

  • Neurogene's EPS (Basic) rose 1680.67% to -$0.99 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.11, marking a year-over-year decrease of 11678.92%. This contributed to the annual value of -$4.31 for FY2024, which is 11552.43% down from last year.
  • Latest data reveals that Neurogene reported EPS (Basic) of -$0.99 as of Q3 2025, which was up 1680.67% from -$1.05 recorded in Q2 2025.
  • Neurogene's 5-year EPS (Basic) high stood at $27.76 for Q4 2023, and its period low was -$32.67 during Q3 2023.
  • In the last 3 years, Neurogene's EPS (Basic) had a median value of -$1.09 in 2024 and averaged -$6.13.
  • Within the past 5 years, the most significant YoY rise in Neurogene's EPS (Basic) was 9646.39% (2024), while the steepest drop was 10403.07% (2024).
  • Neurogene's EPS (Basic) (Quarter) stood at $27.76 in 2023, then plummeted by 104.03% to -$1.12 in 2024, then increased by 11.52% to -$0.99 in 2025.
  • Its EPS (Basic) stands at -$0.99 for Q3 2025, versus -$1.05 for Q2 2025 and -$1.08 for Q1 2025.